<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301833</url>
  </required_header>
  <id_info>
    <org_study_id>3000-A14</org_study_id>
    <nct_id>NCT01301833</nct_id>
  </id_info>
  <brief_title>Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes</brief_title>
  <official_title>Long-term Safety Study of MP-513 as Monotherapy or in Combination With Oral Antihyperglycaemic Agent in Japanese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as
      monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2
      Diabetes for 52 weeks administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Treatment-emergent adverse events (TEAE) were defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after receiving the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at Week 52</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 52</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Glucagon at Week 52</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Immuno Reactive Insulin (IRI) at Week 52</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">462</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>teneligliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teneligliptin and glinide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teneligliptin and biguanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teneligliptin and alpha-glucosidase inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teneligliptin</intervention_name>
    <arm_group_label>teneligliptin</arm_group_label>
    <arm_group_label>teneligliptin and glinide</arm_group_label>
    <arm_group_label>teneligliptin and biguanide</arm_group_label>
    <arm_group_label>teneligliptin and alpha-glucosidase inhibitor</arm_group_label>
    <other_name>MP-513</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glinide</intervention_name>
    <arm_group_label>teneligliptin and glinide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biguanide</intervention_name>
    <arm_group_label>teneligliptin and biguanide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-glucosidase inhibitor</intervention_name>
    <arm_group_label>teneligliptin and alpha-glucosidase inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who has been receiving a stable dose and regimen of oral antihyperglycaemic
             agent (biguanide agent,α-glucosidase inhibitor,rapid insulin secretagogue) for
             diabetes over 12 weeks before administration of investigational drug

          -  Patients who are under dietary management and taking therapeutic exercise for diabetes
             over 12 weeks before administration of investigational drug

          -  Patients whose HbA1c is between 6.5% - 10.0%

          -  Patients who were not administered diabetes therapeutic drugs prohibited for
             concomitant use within 12 weeks before administration of investigational drug

        Exclusion Criteria:

          -  Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or
             secondary diabetes (Cushing disease, acromegaly, etc)

          -  Patients who are accepting treatments of arrhythmias

          -  Patients with serious diabetic complications

          -  Patients who are habitual excessive alcohol consumption.

          -  Patients with severe hepatic disorder or severe renal disorder.

          -  Patients who are pregnant, lactating, and probably pregnant patients, and patients who
             can not agree to contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takashi Kadowaki, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Tokyo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazuoki Kondo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chitose-shi</city>
        <state>Hokkaidou</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Kadowaki T, Marubayashi F, Yokota S, Katoh M, Iijima H. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies. Expert Opin Pharmacother. 2015 May;16(7):971-81. doi: 10.1517/14656566.2015.1032249. Epub 2015 Apr 10.</citation>
    <PMID>25861982</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <results_first_submitted>July 31, 2015</results_first_submitted>
  <results_first_submitted_qc>July 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2015</results_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biguanides</mesh_term>
    <mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Teneligliptin</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )</description>
        </group>
        <group group_id="P2">
          <title>Teneligliptin and Glinide</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide</description>
        </group>
        <group group_id="P3">
          <title>Teneligliptin and Biguanide</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide</description>
        </group>
        <group group_id="P4">
          <title>Teneligliptin and Alpha-glucosidase Inhibitor</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal matter</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Teneligliptin</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )</description>
        </group>
        <group group_id="B2">
          <title>Teneligliptin and Glinide</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide</description>
        </group>
        <group group_id="B3">
          <title>Teneligliptin and Biguanide</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide</description>
        </group>
        <group group_id="B4">
          <title>Teneligliptin and Alpha-glucosidase Inhibitor</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="95"/>
            <count group_id="B4" value="75"/>
            <count group_id="B5" value="462"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Treatment-emergent adverse events (TEAE) were defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after receiving the last dose of study drug.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Safety set, consisting of all patients, who received at least one dose of study drug and who had at least one safety data after the treatment of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teneligliptin</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )</description>
          </group>
          <group group_id="O2">
            <title>Teneligliptin and Glinide</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide</description>
          </group>
          <group group_id="O3">
            <title>Teneligliptin and Biguanide</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide</description>
          </group>
          <group group_id="O4">
            <title>Teneligliptin and Alpha-glucosidase Inhibitor</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Treatment-emergent adverse events (TEAE) were defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after receiving the last dose of study drug.</description>
          <population>Safety set, consisting of all patients, who received at least one dose of study drug and who had at least one safety data after the treatment of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at Week 52</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after the treatment of study drug. Analysis based on last observation carried forward, where the last postbaseline observed value was carried forward and used for Week 52 where data was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Teneligliptin</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )</description>
          </group>
          <group group_id="O2">
            <title>Teneligliptin and Glinide</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide</description>
          </group>
          <group group_id="O3">
            <title>Teneligliptin and Biguanide</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide</description>
          </group>
          <group group_id="O4">
            <title>Teneligliptin and Alpha-glucosidase Inhibitor</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 52</title>
          <population>The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after the treatment of study drug. Analysis based on last observation carried forward, where the last postbaseline observed value was carried forward and used for Week 52 where data was missing.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.64"/>
                    <measurement group_id="O2" value="-0.76" spread="0.70"/>
                    <measurement group_id="O3" value="-0.78" spread="0.75"/>
                    <measurement group_id="O4" value="-0.89" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Week 52</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after the treatment of study drug. Analysis based on last observation carried forward, where the last postbaseline observed value was carried forward and used for Week 52 where data was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Teneligliptin</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )</description>
          </group>
          <group group_id="O2">
            <title>Teneligliptin and Glinide</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide</description>
          </group>
          <group group_id="O3">
            <title>Teneligliptin and Biguanide</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide</description>
          </group>
          <group group_id="O4">
            <title>Teneligliptin and Alpha-glucosidase Inhibitor</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Week 52</title>
          <population>The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after the treatment of study drug. Analysis based on last observation carried forward, where the last postbaseline observed value was carried forward and used for Week 52 where data was missing.</population>
          <units>mg / dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.7" spread="25.5"/>
                    <measurement group_id="O2" value="-13.7" spread="23.7"/>
                    <measurement group_id="O3" value="-12.7" spread="27.1"/>
                    <measurement group_id="O4" value="-19.5" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Glucagon at Week 52</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after the treatment of study drug. Analysis based on last observation carried forward, where the last postbaseline observed value was carried forward and used for Week 52 where data was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Teneligliptin</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )</description>
          </group>
          <group group_id="O2">
            <title>Teneligliptin and Glinide</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide</description>
          </group>
          <group group_id="O3">
            <title>Teneligliptin and Biguanide</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide</description>
          </group>
          <group group_id="O4">
            <title>Teneligliptin and Alpha-glucosidase Inhibitor</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Glucagon at Week 52</title>
          <population>The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after the treatment of study drug. Analysis based on last observation carried forward, where the last postbaseline observed value was carried forward and used for Week 52 where data was missing.</population>
          <units>pg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="12.5"/>
                    <measurement group_id="O2" value="5.3" spread="13.7"/>
                    <measurement group_id="O3" value="5.0" spread="14.4"/>
                    <measurement group_id="O4" value="6.9" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Immuno Reactive Insulin (IRI) at Week 52</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after the treatment of study drug. Analysis based on last observation carried forward, where the last postbaseline observed value was carried forward and used for Week 52 where data was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Teneligliptin</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )</description>
          </group>
          <group group_id="O2">
            <title>Teneligliptin and Glinide</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide</description>
          </group>
          <group group_id="O3">
            <title>Teneligliptin and Biguanide</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide</description>
          </group>
          <group group_id="O4">
            <title>Teneligliptin and Alpha-glucosidase Inhibitor</title>
            <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Immuno Reactive Insulin (IRI) at Week 52</title>
          <population>The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after the treatment of study drug. Analysis based on last observation carried forward, where the last postbaseline observed value was carried forward and used for Week 52 where data was missing.</population>
          <units>μU / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.988" spread="8.314"/>
                    <measurement group_id="O2" value="0.211" spread="2.378"/>
                    <measurement group_id="O3" value="-0.173" spread="9.093"/>
                    <measurement group_id="O4" value="-0.330" spread="2.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Teneligliptin</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )</description>
        </group>
        <group group_id="E2">
          <title>Teneligliptin and Glinide</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide</description>
        </group>
        <group group_id="E3">
          <title>Teneligliptin and Biguanide</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide</description>
        </group>
        <group group_id="E4">
          <title>Teneligliptin and Alpha-glucosidase Inhibitor</title>
          <description>teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA(15.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Ota's naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis hypertrophic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA(15.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Deafness bilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Conjunctival cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Conjunctival deposit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pingueculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Conjunctivochalasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Normal tension glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Mumps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Peritonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gingival abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Mycoplasma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dental gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Chillblains</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Helicobacter test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nodal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Allergic pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vocal cord disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dandruff</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dyshidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials, Information Desk</name_or_title>
      <organization>Mitsubishi Tanabe Pharma Corporation</organization>
      <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

